首页> 外国专利> MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR (TNF- ) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-

MODULATING THE KV1.1 VOLTAGE-GATED POTASSIUM CHANNEL IN T-CELLS FOR REGULATING THE SYNTHESIS AND SECRETION OF TUMOR NECROSIS FACTOR (TNF- ) AND TREATING HUMAN DISEASES OR INJURIES MEDIATED BY DETRIMENTALLY HIGH OR LOW LEVELS OF TNF-

机译:调节T细胞中的KV1.1电压门控钾通道,以调节肿瘤坏死因子(TNF-)的合成和分泌,并治疗人为疾病或由TNF-α高低引起的疾病或伤害

摘要

Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-alpha, and thus can be used for eradication of cancer, improved eradication of infectious organisms, increased permeability of blood vessels and the blood brain barriers to given molecules and cells, and improved neuronal features, regeneration function and development. Blocking the voltage-gated potassium channel Kv1.1 of T-cells causes the robust and exclusive production of TNF-alpha. Similarly, unblocking of a blocked Kv1.1 channel or opening of a Kv1.1 channel will prevent the T-cells from producing and secreting excess amounts of TNF-alpha, thus being useful in the treatment of conditions such as rheumatoid arthritis and for treating neurological diseases associated with defected functioning and/or pathological block of the Kv1.1 channel, among them PNH associated with Kv1 Abs; Encephalitis associated with Kv1 Abs; and Episodic-ataxia type 1 (EA-1), in all of which the T-cell blocked Kv1.1 channel may secrete excess TNFa and thereby contribute to the pathology. Blocking of the Kv1.1 channel may be achieved in vivo or ex vivo by contact with a selective Kv1.1 channel blocking molecule such as Dendrotoxin-K or a selective monoclonal antibody against the Kv1.1 channel. Preventing the Kv1.1. block would be achieved by Kv1.1 openers, or by molecules that would prevent the closure of the Kv1.1 channel.
机译:阻断T细胞的电压门控钾通道Kv1.1会导致TNF-α的强大和排他性生产,因此可用于根除癌症,改善根除传染性生物体,增加血管和血脑的通透性给定分子和细胞的障碍,以及改善的神经元功能,再生功能和发育。阻断T细胞的电压门控钾通道Kv1.1会导致TNF-α的强大和排他性生产。类似地,解除封闭的Kv1.1通道的封闭或打开Kv1.1通道将防止T细胞产生和分泌过量的TNF-α,因此可用于治疗类风湿性关节炎和治疗与Kv1.1通道功能障碍和/或病理性阻断相关的神经系统疾病,其中包括与Kv1 Abs相关的PNH;与Kv1抗体相关的脑炎;和Episodic共济失调1型(EA-1),在所有这些中,T细胞都阻断了Kv1.1通道,可能分泌过量的TNFa,从而助长了病理。 Kv1.1通道的封闭可通过与选择性Kv1.1通道封闭分子(例如Dendrotoxin-K)或针对Kv1.1通道的选择性单克隆抗体接触而在体内或离体实现。防止Kv1.1。 Kv1.1开启子或阻止Kv1.1通道关闭的分子可以达到阻断作用。

著录项

  • 公开/公告号EP1917275A4

    专利类型

  • 公开/公告日2009-01-28

    原文格式PDF

  • 申请/专利权人 MINEUET THERAPEUTICS LTD.;

    申请/专利号EP20060789358

  • 发明设计人 LEVITE MIA;

    申请日2006-08-03

  • 分类号C07K14/525;C12N5/06;C12N5/08;

  • 国家 EP

  • 入库时间 2022-08-21 19:17:15

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号